By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Adamas Pharmaceuticals 

1900 Powell Street
Suite 1050
Emeryville  California  94608  U.S.A.
Phone: 510-450-3500 Fax: 510-428-0519




Company News
Allergan (AGN) And Adamas Pharmaceuticals (ADMS) Announce New Expanded Indication For NAMZARIC (Memantine And Donepezil Hydrochlorides) Extended Release For The Treatment Of Moderate To Severe Alzheimer's Disease 7/19/2016 6:27:57 AM
Adamas Pharmaceuticals (ADMS) Announces Data Update At The 68th American Academy of Neurology Annual Meeting 4/15/2016 7:59:01 AM
Adamas Pharmaceuticals (ADMS) Provides Review Of 2015 And Projected Future Milestones 1/13/2016 7:24:16 AM
Adamas Pharmaceuticals (ADMS)' Lead Drug ADS-5102 Meets Phase III Goals; Stock Surges 12/23/2015 6:33:04 AM
Adamas Pharmaceuticals (ADMS) Reports Third Quarter 2015 Financial Results 11/13/2015 8:23:37 AM
Adamas Pharmaceuticals (ADMS) To Present At The 24th Annual Credit Suisse Healthcare Conference 10/27/2015 2:23:02 PM
Adamas Pharmaceuticals (ADMS) Reports Second Quarter 2015 Financial Results 8/12/2015 11:16:17 AM
Adamas Pharmaceuticals (ADMS) Completes Recruitment Of Its Phase III EASE LID Study Evaluating ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia Associated With Parkinson's Disease 7/10/2015 6:53:27 AM
Adamas Pharmaceuticals (ADMS) Issued U.S. Patent Relating To ADS-5102 Program 7/8/2015 7:16:47 AM
Adamas Pharmaceuticals (ADMS) To Present At The Cantor Fitzgerald InauguralHealthcare Conference 6/25/2015 12:04:59 PM